Core Viewpoint - The company, Yidu Tech (02158), has demonstrated healthy business growth with a significant improvement in financial performance, highlighted by a notable increase in revenue and adjusted EBITDA, while also engaging in share buybacks to enhance shareholder value [1] Financial Performance - For the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, indicating a near breakeven point on the accounting level [1] - The achievement of this financial milestone occurred about one year earlier than the management's previous expectations [1] Market Sentiment - Brokerage firms are releasing positive signals regarding Yidu Tech, with Everbright Securities highlighting the company's continuous breakthroughs in AI medical innovation [1] - Yidu Tech's medical large model has begun to establish a "data + algorithm + scenario" closed-loop system, accelerating the application of technology across multiple scenarios [1] - Citigroup has maintained a "Buy" rating for the company, setting a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [1] Share Buyback - On December 3, the company repurchased 392,000 shares at a price of HKD 5.09 per share, with a total repurchase amount of approximately HKD 2 million [1]

Group 1 - The company, Yidu Tech (02158.HK), announced the issuance of a total of 1,958,000 shares as part of its share award plan, which represents approximately 0.18% of the total issued shares as of the announcement date, excluding treasury shares [1] - The share issuance is contingent upon acceptance by the three award recipients [1] - The announcement was made on December 3, 2025 [1]

Core Viewpoint - Yidu Tech (02158) announced that on December 3, 2025, the company will grant a total of 1.958 million shares to three reward recipients under its post-IPO share incentive plan, representing approximately 0.18% of all issued shares as of the announcement date, excluding treasury shares, pending acceptance by the recipients [1] Company Summary - Yidu Tech will issue 1.958 million shares as part of its share incentive plan [1] - The shares granted will account for about 0.18% of the total issued shares, excluding treasury shares [1] - The issuance is contingent upon acceptance by the reward recipients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 根據股份獎勵計劃授出股份獎勵 於2025年12月3日，本公司根據首次公開發售後股份獎勵計劃，通過發行新股份（定 義見上市規則第17章）向3名獎勵承授人授出合共1,958,000股獎勵股份，佔於本公告 日期全部已發行股份（不包括庫存股）約0.18%，惟須待獎勵承授人接納後方可作 實。 已授出獎勵的詳情如下： | 授出日期： | 2025年12月3日 | | --- | --- | | 獎勵承授人數量： | 3名 | | 已授出獎勵數目： | 1,958,000份 | | 獎勵股份代價： | 無 | | 於授出日期股份的 | 每股股份5.10港元，按於授出日期聯交所所報之收市價 | | 市價： | 計算 | – 1 – Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 授出股份獎勵 本公告乃根據上市規則第17.06A、17. ...

Core Viewpoint - The company, Yidu Tech (02158), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will spend HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranges from HKD 5.07 to HKD 5.10 [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback on December 3, 2025, spending HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranged from HKD 5.07 to HKD 5.10 [1]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on December 3, 2023, spending HKD 1.995 million to repurchase 392,000 shares at a price range of HKD 5.07 to 5.10 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 392,000 shares at a total cost of HKD 1.995 million [1] - The repurchase price per share ranged from HKD 5.07 to HKD 5.10 [1]

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月31日 | 1,063,856,231 ...

Core Viewpoint - Neusoft Group, a veteran software giant, has recently secured significant orders in the smart cockpit domain, totaling approximately 4.2 billion yuan, following a previous order of 5.6 billion yuan. However, the company has been experiencing prolonged financial difficulties, with a net profit decline of 66.47% year-on-year for the first three quarters of 2025, raising concerns about its operational viability and market competitiveness [1][3][4]. Financial Performance - The latest financial report indicates that Neusoft's revenue for Q3 2025 reached 2.802 billion yuan, an 8.13% year-on-year increase, while the cumulative revenue for the first three quarters was 7.491 billion yuan, up 8.72% year-on-year [4][5]. - Despite revenue growth, the net profit attributable to shareholders for Q3 was -5.1886 million yuan, a significant decline of 109.59% year-on-year, and the cumulative net profit for the first three quarters was approximately 51.08 million yuan, down 66.47% year-on-year [4][5][6]. Industry Position and Competitiveness - Neusoft has been in a continuous loss situation for three and a half years, with total losses amounting to 756 million yuan. The company has multiple subsidiaries, including Neusoft Medical and Neusoft Ruichi, all reporting losses exceeding 150 million yuan collectively [4][5]. - The software industry generally enjoys high gross margins, typically between 30% to 80%. However, Neusoft's gross margin for Q3 2025 was only 23.71%, with its smart automotive interconnect business showing a particularly low gross margin of 14.26% [5][6][8]. Business Diversification and Challenges - Neusoft has attempted to diversify its business into areas such as healthcare, smart automotive interconnect, and smart cities. However, revenue growth in these sectors has been underwhelming, with significant declines in growth rates compared to previous years [10][11]. - The company’s R&D investment has been relatively low, with a ratio of R&D expenditure to revenue at only 7.97% in 2024, compared to over 20% for its peers, indicating a lack of commitment to technological advancement [13][14]. Historical Context and Strategic Decisions - Neusoft's origins trace back to 1991, initially focusing on outsourcing services, which contributed significantly to its early revenue growth. However, this model has limited the company's ability to develop core technologies [14][15]. - The company has undergone multiple attempts to capitalize on its subsidiaries through IPOs, with mixed results. Neusoft Medical and other subsidiaries have faced challenges in meeting listing requirements, raising questions about the maturity of their business models [20][21]. Capitalization Strategy - Neusoft has shown a strong inclination towards capitalizing on its business ventures, often prioritizing financial maneuvers over technological development. This approach has led to skepticism regarding its long-term viability in a rapidly evolving tech landscape [19][22]. - Recent acquisitions, such as the purchase of a majority stake in a technology firm, have been viewed as efforts to enhance its market presence, although the legitimacy of these transactions has been questioned due to their complex ownership structures [22][23].

Core Insights - The "2025 AI for Healthcare Hackathon" successfully concluded in Beijing, showcasing a diverse range of innovative teams from top hospitals, renowned universities, and tech companies, emphasizing a shift from traditional tech competitions to a demand-driven, AI-centric healthcare innovation platform [1][8] - The event highlighted the emergence of AI healthcare projects with both cutting-edge technology and clinical application potential, addressing real-world healthcare needs [1][6] Awards and Recognitions - Notable projects included the "Clinical Trial Intelligent Entry and Exit Review Agent," which achieved end-to-end automation in clinical trial participant screening, and various AI assistants targeting specific medical conditions such as hepatitis B and rare diseases [3][6] - The event also recognized projects focused on enhancing healthcare management and service quality, such as the AI health rumor debunking tool and the foreign patient healthcare assistant [3][7] Evaluation and Support - A multidisciplinary panel of experts from academia, industry, and investment participated in the evaluation process, ensuring a comprehensive assessment of both technological innovation and clinical applicability [5][8] - The hackathon benefited from the support of the medical AI development platform provided by Yidu Tech, which offered resources and training to participating teams, significantly lowering the barriers to AI healthcare application development [5][6] Innovation and Future Directions - The awarded projects collectively represent a new generation of AI healthcare agents that are capable of understanding complex intentions, executing multi-step tasks, and collaborating with human experts [8][9] - The event underscored the importance of focusing on high-value niche scenarios and building sustainable service models in the era of "AI + Healthcare" [9]